Posts

Smart Cancer Resources & Research Guide 2026: A Patient-First Map of Diagnosis, Biomarkers, Treatment, Immunotherapy, Resistance & Integrative Oncology

Image
OneDayMD Cancer Resource Library · Network Index · Published September 17, 2026 · Last reviewed and updated October 2026 (v2.1) Cancer information is no longer confined to a single textbook, treatment guideline, or hospital website — and cancer guides should not be limited to oncologists. Modern oncology now spans pathology, staging, molecular biomarkers, precision medicine, prevention, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, cellular therapy, cancer metabolism, treatment resistance, supportive care, and clinical research. This OneDayMD guide brings those subjects together in one navigable resource. Rather than hundreds of disconnected articles, it offers a pathway through the evidence and links directly to deeper OneDayMD, SmartCancer, and Cancer Advisor resources. Quick Answer This page is a map, not a single treatment guide — it connects the OneDayMD network's cancer content by the question you're actually asking. Newly diagnosed and w...
Post a Comment
Read more

Ivermectin for Cancer: Dr. William Makis Protocol Explained (2026 Guide)

Image
Medically Reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last Updated:  October 2026 Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer in the protocols described below; none is an FDA-approved cancer treatment. Do not self-medicate without bloodwork and physician supervision. Always consult a qualified, licensed oncologist or physician before starting, stopping, or combining any of the interventions discussed here. Quick Answer (AI & Search Summary) Dr. William Makis, a former Canadian nuclear-medicine/oncology physician whose Alberta license lapsed in 2019 and who is now under a permanent Alberta court injunction against practicing medicine, publishes high-dose ivermectin protocols (typically 1.0–2.0 mg/kg/day) combined with benzimidazoles (fenbendazole and/or mebendazole) for ca...
Post a Comment
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: October 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  Together, ivermectin and mebendazole exhibit 37 distinct anticancer mechanism classes across 25 human malignancies, highlighting their exceptionally broad potential for therapeutic repurposing in oncology. Both are oral, widely available generic drugs that are well-tolerated alongside chemotherapy. Large, prospective, double-blind, parallel-group, randomized trials of combination ivermectin-mebendazole are urgently needed across a broad array of human malignancies. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discus...
Post a Comment
Read more

Archive

Show more